Shots:

• Arbutus to receive a $40M up front, $15M in equity investment at $4.19/share representing a premium of 15% on 30-day average closing price and is eligible to receive $245M upon the development, regulatory and sales milestones along with royalties on net sales
• Qilu will be responsible for funding all development and commercialization activities for mainland China, Hong Kong, Macau, and Taiwan
• Arbutus’s AB-729 is currently in multiple P-IIa POC clinical trials in combination with other approved or investigational agents. In clinical results, AB-729 was generally safe and well-tolerated & showed a reduction in hepatitis B surface antigen and hepatitis B DNA

Ref: Globe Newswire | Image: Arbutus